Table 1 Demographics, clinical characteristics, and laboratory findings of COVID-19 patients
Characteristics | Â |
|---|---|
Age, years | 42.6 ± 16.0 |
  < 40 | 16 (51.6%) |
 40–60 | 12 (38.7%) |
  > 60 | 3 (9.7%) |
Sex | |
 Female | 13 (41.9%) |
 Male | 18 (58.1%) |
Hypertension/ diabetes /cardiovascular disease/ cerebrovascular disease/COPD/kidney disease | 8 (25.8%) |
Signs and symptoms | |
 Fever | 29 (93.5%) |
 Cough | 15 (48.4%) |
 Fatigue | 2 (6.5%) |
 Myalgia | 1 (3.2%) |
 Diarrhea | 1 (3.2%) |
Interval from illness onset to CT scan, days | 8.8 ± 5.7 |
Days of clinical intervention before CT scan | 2.6 ± 3.5 |
Proportion of affected lungs calculated by AI (%) | 8.91 ± 15.01 |
  < 5% | 21 (67.7%) |
 5–20% | 5 (16.1%) |
  > 20% | 5 (16.1%) |
Clinical classification according to ncpDTP-7 | |
 Mild | 0 (0.0%) |
 Moderate | 23 (74.2%) |
 Severe | 4 (12.9%) |
 Critical | 4 (12.9%) |
Arterial blood gas on the day of CT scan | |
 PaO2, mmHg | 57.7 ± 19.8 |
  < 60 | 4/6 (66.7%) |
  ≥ 60 | 2/6 (33.3%) |
 PaCO2, mmHg | 42.7 ± 6.8 |
  ≤ 50 | 5/6 (83.3%) |
  > 50 | 1/6 (16.7%) |
Laboratory findings | |
 White blood cell count, × 109/L | 4.80 ± 1.87 |
  < 4 | 13 (41.9%) |
 4–10 | 17 (54.8%) |
  > 10 | 1 (3.2%) |
 Lymphocyte percentage (%) | 30.3 ± 13.3 |
 Lymphocyte count, ×109/L | 1.35 ± 0.59 |
 Neutrophil percentage (%) | 57.4 ± 14.1 |
 Monocyte percentage (%) | 11.0 ± 3.7 |
 Hemoglobin, g/L | 131.4 ± 18.1 |
 AST, U/L | 35.3 ± 28.6 |
  ≤ 40 | 21/30 (70.0%) |
  > 40 | 9 /30 (30.0%) |
 ALT, U/L | 26.7 ± 18.4 |
  ≤ 35 | 25/30 (83.3%) |
  > 35 | 5 /30 (16.7%) |
 CRP, mg/L | 19.2 ± 30.1 |
  ≤ 5 | 10/21 (47.6%) |
  > 5 | 11/21 (52.4%) |
 CK, U/L | 148.3 ± 271.9 |
  ≤ 200 | 25/28 (89.3%) |
  > 200 | 3/28 (10.7%) |